Moleculin Biotech vs SELLAS Life Sciences
MBRX and SLS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How MBRX and SLS compare
SELLAS Life Sciences is the larger company, worth 193 times as much as Moleculin Biotech ($1.6B against $8.2M).
SELLAS Life Sciences scores higher on the StockData Score (7 against 6 for Moleculin Biotech), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | MBRX | SLS |
|---|---|---|
| Size and price | ||
| Market cap | $8.2M | $1.6B |
| Share price | $7.87 | $7.86 |
| Change, 1 year | −96.8% | 428% |
| Change, 5 years | −100.0% | 12.1% |
| Beta (5Y) | 1.17 | 1.48 |
| Employees | 150K | 13 |
| StockData Score | ||
| Total score | 6 | 7 (better) |
| Valuation score | 1 (better) | 0 |
| Growth score | 0 | 0 |
| Performance score | 0 | 1 (better) |
| Health score | 5 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 0.6× (better) | 12.0× |
| Profitability | ||
| Return on equity | – | −40.3% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 1.37 | 14.92 (better) |
| Altman Z-score | −19.51 | 99.73 (better) |
| Piotroski F-score | 3 | 4 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 0.89% | 36.5% |
| Held by insiders | – | 1.8% |
| Insider net buying, 12 months | – | $0 |
| Short interest, % of float | – | 28.8% |
Go deeper
- MBRX stock overview
- MBRX income statement
- MBRX valuation and score
- SLS stock overview
- SLS income statement
- SLS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.